fbpx Skip to main content

Accelerating diversity, equity & inclusion in life science.

The Next 25

Explore our new brand identity

Take Action

Tell Congress to Oppose Price Setting


Our Story

Biocom California is the indisputable leader in accelerating life science in California. We accelerate our members’ success by advocating for innovation, removing barriers to doing business, and connecting people, talent, and capital. We represent a place where revolutionary research is routine and fearless innovation is business as usual. A home for those with the audacity to think they can change the world. Because California is more than a spot on the map—it’s a state of mind. A state of progress.

About Us

H.R. 3 Lower Drug Costs Now Act

H.R.3 is an international reference pricing measure introduced in the House of Representatives. The bill proposes setting prices for innovative medicines in the U.S based on the prices foreign countries with different health care systems pay for those medicines. Importing price controls would threaten the development of new treatments and cures and jeopardize patient access to medicines.

Passing H.R.3 threaten California’s world-class innovative biopharmaceutical sector, decreasing the development of new treatments and cures for patients around the world. Biocom California strongly opposes H.R.3 and has advocated against its progress on behalf of our member organizations.

Learn More


Take advantage of 30+ RFP-vetted life science-related contracts.


In-Person Events Survey Results
Learn More

See the data on returning to face-to-face gatherings.

Biocom California Strongly Opposes TRIPS Waiver
Learn More

Read our response to the White House’s support of the proposal.

Biocom California Institute Career Lab
Learn More

Explore the California life science industry’s go-to career resource.

Our Members
Learn More

Get to know our growing list of 1,400+ member companies.

“I have had the opportunity to give presentations to VCs and Pharma Venture Funds at several Venture Day events. These experiences have been very helpful with respect to meeting investors from outside the San Diego area and also for valuable feedback. This is an important Biocom program!”
Michael J. Newman, CEO, Decoy Biosystems
“The LSYL (Life Science Young Leaders) series is a terrific idea. It’s just easier to make meaningful connections among contemporaries and this series is a great platform for that. I look forward to the next one.”
Brendan McCarthy, Attorney, Gunderson Dettmer Stough Villeneuve Franklin & Hachigan
“I was impressed with Biocom’s DeviceFest & Digital Health Conference on August 29th, 2018. The conference had a balance view of content and discussion time with industry experts, which allowed us to have deeper introductory meetings, which will lead to deeper relationships with experts from all over North America. Great job by the planning committee and the management of Biocom.”
Dipak Shah, Board Member, Obsidio Therapeutics, Inc.